Physician profile
Dwight D Koeberl
NPI 1023192184
$8,382,232.82
in general payments reported to CMS, 2019-2025
10 companies · $149 in 2025
The $149 reported for 2025 was more than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $2.49 · 2021: $155 · 2022: $1.0M · 2023: $3.9M · 2024: $3.4M · 2025: $149.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Acquisitions: $7.4M · Food and Beverage: $149.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Acquisitions | $7,376,003.68 |
| Food and Beverage | $148.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Asklepios Biopharmaceutical INC. | $7,376,003.68 | 2023-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $1,005,900.56 | 2022 | |
| Amicus Therapeutics, INC. | $154.75 | 2021 | |
| Genzyme Corporation | $148.80 | 2025 | |
| Ultragenyx Pharmaceutical INC. | $22.54 | 2022 | |
| Travere Therapeutics, INC. | $2.49 | 2020 |
4 companies reported research payments only; those appear in the research section below.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dwight Koeberl listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.